Fused heterocyclic indane carboxamide CGRP receptor antagonists

摘要

The present invention is directed to fused heterocyclic indane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

主权项

1. A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: X is selected from C(R4) or N; Y is selected from C(R5) or N; R2 is selected from hydrogen and C1-4alkyl; R1 is selected from the group consisting of: (1) C1-6alkyl, optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of: F, Cl, Br, hydroxy and C1-4alkoxy, (2) C3-6cycloalkyl, optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of: F, Cl, Br, hydroxy and C1-4alkoxy, and wherein R6, R7, R8, R9 and R10 are independently selected from the group consisting of: hydrogen, methyl, F, Cl and Br; R3 is selected from the group consisting of:
(1) hydrogen;(2) C1-6alkyl, optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of: F, amino, hydroxy and C1-4alkoxy, said C1-4alkoxy optionally substituted with hydroxy;(3) C3-6cycloalkyl or a 5- or 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from S, O and N, said C3-6cycloalkyl and heterocyclyl optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of: F and —CF3; and(4) phenyl; R4 is hydrogen or methyl; and R5 is hydrogen, F or CN.